

**Real-Life Trials in Oncology Programme 2023
AWARDS CERTIFICATE**

Prof. Fabrice André, as Chair of the Evaluation Panel of Real-Life Trials in Oncology Programme 2023 on behalf of the Gustave Roussy Foundation and CRIS Cancer Foundation

Certifies that,

On 11st September 2023 the Evaluation Panel held the Evaluation Meeting for the Awardee selection of Real-Life Trials in Oncology Programme 2023.

The attendees to the evaluation meetings were the following:

- Prof. Alexandra Leary – Gustave Roussy - FR
- Prof. Joaquín Martínez - H12O-CNIO – SP
- Prof. Fabrice André – Gustave Roussy - FR
- Prof. Michel Ducreux – Gustave Roussy - FR
- Mr. Antonio López – CNIO – SP – Secretariat Lead

Excused their absence:

- Prof. Benjamin Besse – Gustave Roussy - FR
- Prof. Emiliano Calvo – HM CIOCC - SP
- Prof. Fernando Rico-Villademoros – COCIENTE S.L. - SP

During the meeting, the panel unanimously agreed to Award the following candidates:

- **RLTiO2023_09 – SEVENAZA** - Christophe Willekens (Institut Gustave Roussy) and Pau Montesinos (Hospital Universitari i Politècnic La Fe) - A randomized Phase III study evaluating a reduced Venetoclax exposure to seven days versus standard continuous Venetoclax exposure combined with Azacitidine in treatment naïve subjects with Acute Myeloid Leukemia who are ineligible for standard induction therapy.
- **RLTiO2023_08 – LOWTOX-RLT** - Eric Baudin (Institut Gustave Roussy) and Rocío García-Carbonero (Hospital Universitario 12 de Octubre) - Randomized trial of Lu177-Dotatate every 8 versus every 16 weeks in non-aggressive G1-2 advanced midgut neuroendocrine tumors (NETs).
What I sign in conformity with all Members of the Evaluation Panel.

Paris, 14th November 2023


Prof. Fabrice Andre
Chair of the RLTiO Evaluation Panel